Gordon Hamilton MD, CEO, will be participating in the RNA Leaders Europe Congress in Basel, this coming week, 15 – 16 March.

RNA Leaders is an important event in the RNA space, which is dominating a lot of innovations in genetic medicine, both as a therapeutic but also as a source of druggable targets. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules and non-linear RNAs are emerging.

Depixus will be presenting a poster entitled ‘MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’, where, using examples, we discuss how our state-of-the-art technology platform, MAGNA™ can be used to study complex biomolecular interactions between nucleic acids and small molecules, a topic that is gathering significant excitement in the pharmaceutical industry. We look forward to meeting you at RNA Leader

Dr Christine Blancher, Head of Applications & Collaborations and Dr Zhen Wang, Principal Scientist at Depixus, will be participating in the CHI Drug Discovery Conference section on ‘RNA-Targeting Small Molecule Drugs’, from 11 — 12 April, in San Diego. They will be presenting posters entitled ‘MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’ and ‘Single molecule analysis of nucleic acid structure — small molecule interaction and molecular dynamics using MAGNA™’, respectively.

Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia, focused on discovery and optimization challenges of small molecule drug candidates.

We look forward to seeing you there!